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Abstract
Background: To assess reasons for continuing practice variation in the management of childhood nephrotic
syndrome despite expert reviews and guidelines, we are conducting a longitudinal cohort study in children with
glucocorticoid sensitive nephrotic syndrome.
Objectives of this mid-study report are to describe patient and physician recruitment characteristics, glucocorticoid
prescriptions, use of second line agents, biopsy practices, and adherence to study protocol.
Methods: Children with new onset nephrotic syndrome and providers are being recruited from all 12 pediatric
nephrology centres across Canada with > 2½ years follow-up. Data collection points of observation are over a
minimum 36months. Details of prescribed glucocorticoids and of all second line agents used during treatment are
being collected. All relapses are being recorded with time to urinary remission of proteinuria.
Results: To date, 243 patients (57.1% male) from 12 centres were included. Median number of patients per centre was
29 (range 2–45), and median age of cohort was 7.3 (IQR 4.2) at enrollment. Forty-eight physicians were recruited,
median 5 (range 2–8) per site. Median number of relapses per patient year of follow-up was 2.1 (IQR 4). Cumulative
dose variability of glucocorticoids prescribed per episode of proteinuria and length of treatment was observed
between participating centres.
Conclusion: The Canadian pediatric nephrology community established a longitudinal childhood nephrotic syndrome
cohort study that confirms ongoing practice variability. The study will help to evaluate its impact on patient outcomes,
and facilitate clinical trial implementation in nephrotic syndrome.
Keywords: Nephrotic syndrome, Children, Longitudinal study, Glucocorticoids, Practice variation
Background
Childhood nephrotic syndrome is characterized by se-
vere proteinuria and hypoalbuminemia, with edema as
the most common presenting symptom [1, 2]. The
majority of (> 90%) children with nephrotic syndrome
will have minimal change disease and enter remission of
proteinuria with glucocorticoid treatment. While the
goal of initial therapy is to maximize the proportion of
patients with sustained remission, many patients experi-
ence relapses (range of 1 to > 20 relapses during child-
hood) that can lead to significant morbidity [3].
Nephrotic syndrome is associated with increased health
system costs which include multi-disciplinary specialist
health care team visits, hospital admissions for edema
control, infection or vascular thrombosis, and the need
for diagnostic kidney biopsies during disease course [4].
The evidence base for treatment of first presentation
and relapses of nephrotic syndrome has been synthe-
sized in reviews, local guidelines [5], and in an inter-
national clinical practice guideline [6]. There is a lack of
consensus regarding best treatment approaches in many
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aspects of nephrotic syndrome care, including initial
treatment, diagnostic approach and treatment of
relapses. Our group and others have demonstrated that
variation in care is common and that there are centre,
physician and patient related factors influencing vari-
ation in care [7–9]. However, the impact of existing
treatment variation on nephrotic syndrome relapse rates
and other outcomes in children remains under studied.
Without a careful longitudinal analysis and randomized
controlled trials, providers cannot determine whether
treatment protocol standardization may lead to im-
proved patient and health care cost outcomes.
We are undertaking a unique, Canada-wide longitudinal
cohort study of patients with glucocorticoid sensitive neph-
rotic syndrome and of the treatment practices of physicians
caring for these patients, to address the knowledge gap on
the association of nephrotic syndrome treatment variation
with relapse rates. The design and methods of this paper
have been published previously [10]. The measures used
and associations examined in this study are novel, and in-
clude evaluating associations between centre-, physician-
and patient-level characteristics with glucocorticoid pre-
scriptions, duration of glucocorticoid treatment and relapse
rates. Moreover, the feasibility, and recruitment potential
were unknown when this national study was launched.
Therefore, our objectives are to describe recruitment, pa-
tient and physician characteristics, glucocorticoid prescrip-
tions, use of second line agents, biopsy practices, and
adherence to study protocol.
Methods
Study design and participants
Ethics approval and consent to participate
Ethics approval was obtained from the University of Cal-
gary Conjoint Health Research Ethics Board (REB13–0059)
in 2013, and subsequently, the study was approved by
research ethics boards at all participating sites. Other site
ethics numbers are: SickKids Research Ethics Board REB
1000021384; University of Manitoba Bannatyne Campus Re-
search Ethics Board (Health Research Ethics Board – HREB)
HS16933 (H2013:420);
University of Saskatchewan Bio-REB # 14–277;
University of Alberta Pro00037781;
University of British Columbia Children’s and Women’s
Health Research Ethics Board H13–03068; IWK Research
Ethics Board 1016972; CHU Sainte-Justine L’approbation
éthique 3950; McGill University Health Centre 13–84-PED;
Children’s Hospital of Eastern Ontario Research Institute
Research Ethics Board 14/188X; Western University Health
Science Research Ethics Board 105459; and McMaster Uni-
versity Hamilton Integrated Research Ethics Board15–384.
Written parental/guardian consent and patient assent as
applicable, were obtained prior to initiating study activities.
Written consent was also obtained from physicians before
their participation. Funding for the study was provided by
the Canadian Institutes of Health Research Project Grant
(MOP142271), Kidney Foundation of Canada (140020) and
Nephcure Foundation. The funders had no role in the de-
sign or conduct of the study, nor in the analysis or inter-
pretation of data.
Eligibility criteria
All children (age 1–18) who present to the pediatric neph-
rology clinics with a clinical diagnosis of nephrotic syn-
drome are eligible for enrollment into this longitudinal
cohort study. Twelve major pediatric nephrology centers in
Canada are participating in this study and details of these
centres have been published previously [10]. In Canada, the
majority of patients with nephrotic syndrome are cared for
in academic health centres, with a few exceptions in major
cities where there are community pediatric nephrologists
(1–3 per major site). All pediatric nephrologists who care
for children with nephrotic syndrome at participating sites
are also eligible for enrollment in order to evaluate phys-
ician characteristics specific to each prescription.
Inclusion and exclusion criteria for patients are shown in
Table 1. Patients may be enrolled at first presentation of
nephrotic syndrome or at their first or second relapse. Pa-
tients < 1 year of age are excluded due to higher prevalence
of genetic cause of nephrotic syndrome and probability of
glucocorticoid resistance. We also exclude patients with
secondary nephrotic syndrome due to other diseases such
as IgA nephropathy and systemic lupus erythematosus.
Enrollment period
Enrollment began at the first participating site in August
2013, and all remaining sites started recruitment in the
following 12 months. Enrollment will continue until
December 2019, for a target recruitment of 400 patients.
The observation period will be extended for an add-
itional 6 months after the enrollment period (until June
2020, to ensure a minimum 6months follow-up for all
patients by the end of study).
Data collection time points
Study data are being collected at the following time points
in the patients’ disease course: 1) at study entry (first pres-
entation, first relapse or second relapse); 2) at the begin-
ning of all relapses occurring during the observation
period [defined as either proteinuria > 3+ on urine
dipstick, > 3 g/L by quantitative urine chemistry, or urine
protein to creatinine ratio > 200mg/mmol, for 3 consecu-
tive days or start of full dose glucocorticoids (60mg/m2/
day or 2mg/kg/day)] [6]; 3) at the end of first presentation
and end of all subsequent relapses [defined as both remis-
sion of proteinuria – negative or < 0.3 g/L [< 1+] protein
on dipstick for 3 consecutive days, and off glucocorticoids]
[6]; 4) study visits every 6months during remission; 5) at
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start of all glucocorticoid sparing agents; 6) at time of all
kidney biopsies; and 7) study end (defined by end of obser-
vation, discharge from clinic or exclusion due to identifica-
tion of an underlying diagnosis as a cause of nephrotic
syndrome). For patients recruited at first or second relapse,
the data from first presentation and/or first relapse are
being collected retrospectively. The data collection time-
lines are outlined in Fig. 1.
Definition of a study “episode” and data collected during
episodes
An ‘episode’ refers to glucocorticoid treatment schedule
used for the first presentation of nephrotic syndrome and
all relapses. Therefore, an episode will begin at the time of
start of full dose glucocorticoid therapy (60mg/m2/day or
2mg/kg/day) and will continue until cessation of glucocor-
ticoids or re-start of full dose glucocorticoids such as in pa-
tients who relapse while tapering glucocorticoids during an
episode. Figure 2 illustrates definition of episodes in the
study. Each prescription protocol is recorded by entering
the total dose prescribed for specific dates, with all
changes in dose for the taper. For each episode, we are re-
cording urine dipstick results (in SI units) at the start of
treatment with glucocorticoids, and relapses are defined as
above using standard definitions. Data regarding urine re-
mission dates are also being recorded. For both relapse and
remission, home or point-of-care dipstick urine protein
and/or urine dipstick results from laboratory testing, or
protein to creatinine results are acceptable in the study
protocol. Patient height and weight are recorded with each
Table 1 Inclusion and exclusion criteria for study
First Presentation First Relapse Second Relapse
Inclusion Criteria Age 1 to ≤17.5 years 1 to ≤17.5 years 1 to ≤17.5 years
Proteinuria > 3+ on dipstick; > 3 g/L on
urinalysis; urine protein to
creatinine ratio > 200mg/mmol,
for 3 consecutive days
> 3+ on dipstick; > 3 g/L on
urinalysis; urine protein to
creatinine ratio > 200mg/mmol,
for 3 consecutive days
> 3+ on dipstick; > 3 g/L on
urinalysis; urine protein to
creatinine ratio > 200mg/mmol,
for 3 consecutive days
Serum Albumin < 25 g/L < 25 g/L < 25 g/L
Exposure to
Glucocorticoids
No prior exposure to
glucocorticoids
Could have prior exposure to
glucocorticoids (at First
Presentation)
Could have prior exposure to






Exclusion Criteria A primary disease associated with nephrotic syndrome (e.g. lupus, malignancy)
Serum C3 concentration low; suggesting alternative cause of nephrotic syndrome
Patients ultimately shown to be glucocorticoid resistant will be excluded from the final analysis (but will continue to be followed)
Fig. 1 Data collection time points during observation
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prescription to allow for calculation of body surface area or
mg/kg dosing.
Prescriptions are linked to the physician who prescribed
it if he/she consented to be part of the study, and all physi-
cians are grouped by the participating center. For physi-
cians who either declined consent or were filling in
temporary positions (locums), we did not collect or record
identifying information and coded their prescriptions as
‘unknown’ physician in the study with no known
demographics.
Therefore, the study dataset is hierarchical in that pa-
tients are linked to the physician who prescribed glucocor-
ticoids, and physicians and patients are grouped by site.
Health data are collected during clinic visits to nephrol-
ogists (every six months after entry into study), including,
height, weight, interim medical history (changes in health
status, revision of diagnosis, new diagnoses), and urine
protein-to-creatinine or albumin-to-creatinine ratios (only
in one centre) during remission. Dose and duration of
treatment (start and end dates) with all second line agents
(e.g. pulse intravenous methylprednisolone, cyclophospha-
mide, tacrolimus, cyclosporine, mycophenolate, rituximab,
levamisole) are recorded in the data.
Analysis
Due to the hierarchical nature of our dataset, we ana-
lysed the data at 3 levels – patient, physician, and site.
We used means, medians and proportions to describe
the patient, physician cohort and site characteristics ac-
cording to key demographics. The patient recruitment
over calendar years will be reported.
a
b
Fig. 2 Defining an episode, illustrating sample scenarios. An episode is defined as the time from start of full dose glucocorticoid therapy (60mg/m2 or
2mg/kg) to cessation of glucocorticoids (a) or re-start of full dose glucocorticoids as in glucocorticoid dependent patients who relapse while tapering
glucocorticoids. (b) Note that the glucocorticoid tapering mode may vary between prescribers. Abbreviation: SD – step down
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Episodes as defined in this study includes both first
presentation and relapses. Relapses were defined as all
episodes recorded apart from first presentation episodes.
Median number of relapses per person year of observa-
tion for the cohort was calculated.
We determined glucocorticoid exposure for the entire
cohort and for patients grouped by site. For the cohort,
we determined the median glucocorticoid exposure for
first presentation and relapses (dose and duration of
therapy). For the purpose of the study, prednisone and
prednisolone were used equivalently. We reported vari-
ation in cumulative prednisone or prednisolone pre-
scribed for episodes and length of episodes by site in
mg/m2, when all patients within a site were grouped.
Maximum and minimum median values between sites
were determined, and variation within site was depicted
using box plots. Finally, we reported summary statistics
of the use of second line agents and biopsy practices
observed in the cohort, as well as measures of adher-
ence to study protocol. We did not impute values for
missing data. We analysed all data until the last active




Between August 2013 and August 2017, a total of 269
patients were screened and 262 were found to be eli-
gible. Of these, 243 (92.8%) were enrolled into the
cohort. For the remainder, 10 declined consent, 3 did
not consent due to language barrier, and 6 were not con-
sented for other reasons. Out of 243 enrolled, 215
(88.5%) were enrolled at first presentation, 18 (7.4%) at
first relapse, and 10 (4.1%) at second relapse. The me-
dian age was 7.3 (IQR 4.2) years at enrollment; the vari-
ability in age at enrollment is shown in Fig. 3. There
were 140 (57.6%) boys and 103 (42.4%) girls. The median
patient years of follow-up in the cohort was 1.0 (IQR 1.6)
years. We are enrolling primarily patients at first presenta-
tion currently (78% new presentations in 2014 versus 97%
new presentations in 2017). The study protocol mandates
that all eligible patients at each site are screened for en-
rollment. It is possible that in some sites that all patients
who presented were not screened due to lack of a study
coordinator for certain periods of time. The number of
missed patients at each site is expected to be low due to
the rare incidence of disease in general. Of note, the
largest site SickKids Hospital in Toronto agreed to enroll
30 patients due to feasibility and funding issues, based on
an a prori agreement with study team.
The average recruitment rate over the calendar years
of September 2013 to December 2017 was 3.9 cases/
month. Monthly variation in enrollment and episodes
recorded were noted as seen in Fig. 4.
Physician cohort descriptors
There were a total of 78 physicians registered in the
Canadian Association of Pediatric Nephrologists list at the
time of study initiation, of whom 10 were inactive due to
retirement and lack of a clinical practice. Among the 68
remaining physicians, 50 were deemed eligible and
approached for the study as they were identified as being
involved in providing care to patients with nephrotic
syndrome within an academic health centre setting. Ineli-
gible physicians were pediatric nephrologists who are
practicing in the community, not engaged in clinical
practice (academic positions without clinical care), or do
not provide care to nephrotic syndrome patients through
ambulatory care. Of those eligible, 48 physicians
consented to be enrolled.
The physician cohort included 24 males and 24
females; of these 96% work full-time, 48% were between
40 and 50 years of age and 75% trained in Canada only.
Individual physicians wrote an mean of 16.6 (standard
deviation 13.8, range 1–54) prescriptions. There were
only 4 episodes recorded in the data prescribed by an
‘unknown’ physician.
Site cohort descriptors
The median recruited number of patients by site was 29
(IQR 28, range 2–45) and the median recruited number of
physicians by site was 5 (range 2–8) respectively. There
were 5 sites in Western Canada (4 Provinces), 4 sites in
Ontario, and 3 sites in Quebec and Eastern Canada (3
Provinces). The enrollment numbers roughly represent
the size of the centre, except for the largest site (SickKids
Hospital, Toronto) which contributed 30 patients based
on a priori recruitment target. Sites with coordinators (6
in total) have a consistent record of enrolling patients
throughout the period of the study. The remaining 6 have
periods of lack of enrollment and in many instances they
are able to back fill recruitment if the patient still fit cri-
teria for enrollment once a coordinator is available. In
Fig. 3 Distribution of age at enrollment into the study
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general, the enrollment numbers reflect the volume of
patients seen at that site.
Among these sites, 7 reported that they were using
protocol based treatments for nephrotic syndrome. The
remainder reported that each physician used a prescrip-
tion that was unique to that physician’s style.
Patient relapse data
The total number of episodes (which includes both first
presentation and relapses) observed was 816 in 243 pa-
tients. The total number of observed relapses was 609 in
243 patients. Overall, median number of relapses per pa-
tient year of follow-up was 2.1 (IQR 0–4). Of 243 patients,
15 (6.4%) were deemed to have glucocorticoid resistance
during observation and were excluded from relapse fre-
quency and glucocorticoid exposure calculations.
After assuming a minimum follow-up of one year for
all patients in this mid-study analysis (to minimize
over-inflation of reported rates due to short lengths of
follow-up), there were 90 (41.3%) patients who experi-
enced ≤1 relapse observed per patient-year of follow -up
(group 1), 100 (45.9%) patients who experienced 1.1 to
3.9 relapses per patient-year of follow-up (group 2), and
28 (12.8%) patients who experienced ≥4 relapses per
patient year of follow-up (group 3).
Glucocorticoid exposure data
Among the 816 episodes captured, 731 (90%) had
complete glucocorticoid prescription data entered and
were used for the glucocorticoid exposure analyses (185
first presentation and 546 relapses). The median cumu-
lative glucocorticoid exposure for first presentation epi-
sode was 3138 (IQR 1333) mg/m2, and relapse episodes
were 1259 (IQR 756) mg/m2 in cohort. The median
length of treatment was 96 days (IQR 39) for first pres-
entation episode and 51 days (IQR 36) days for relapse
episodes in the cohort.
Figure 5 shows that the cumulative glucocorticoid dose
(in mg/m2) per episode (either first presentation or first re-
lapse), varied by site when patients within a site are
grouped. The overall correlations between the cumulative
glucocorticoid dose per episode for patients within a site
were 0.32 [95% CI 0.14–0.57] and 0.09 [95% CI 0.028–
0.26] for first presentation and relapse respectively. The
median absolute deviation (MAD) for the cumulative
glucocorticoid dose within sites for first presentation epi-
sode ranged from 153.4mg/m2 to 820.9mg/m2 and for
relapses ranged from 98.3mg/m2 to 805.9mg/m2.
Second line agents and biopsy practices
Of 243 patients enrolled, 96 (39.5%) patients started
treatment with a second line drug at a median time of
10.8 (IQR 13.6) months from first episode recorded in
the dataset (either first presentation, first or second re-
lapse). The most common second line agent used was
tacrolimus (49, 33.3%), followed by oral cyclophospha-
mide (35, 23.8%), mycophenolate mofetil (26, 17.7%) and
rituximab (22, 14.9%). Among those who received sec-
ond line agent, 19 patients received more than one drug
(1 patient received 4, 2 patients received 3, and 16 pa-
tients received 2 different second line agents). Rituximab
was given at a median time of 15.8 (IQR 23.5) months
from first episode observed.
Biopsies were performed in 56 (23%) children, and two
children had two biopsies. Among the 58 biopsies, most
common reasons for biopsy include initial diagnosis (13;
22.4%), glucocorticoid resistance (11; 18.9%), and gluco-
corticoid dependence (9; 15.5%). Minimal change disease
(36; 62%) was the most common histopathologic diagnosis,
followed by focal segmental glomerulosclerosis in 7 (12%)
children. Other histological diagnoses were acute tubular
necrosis, membranous nephropathy, IgA nephropathy, and
C1q nephropathy.
Fig. 4 Seasonal variation in enrollment and all episodes recorded
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Study protocol adherence
At least one semi-annual visit (routine health data col-
lected during clinic visits to nephrologists every six
months after entry into study) was documented in 208
of 243 (85.6%) enrolled patients, and all of them had at
least one visit not recorded (missing). Of the 208
patients, 11 (5.3%) had < 25% visits completed, 60
(28.8%) had 25 to 75% visits completed and 137 (65.9%)
had > 75% visits completed. Of the semi-annual visits
data forms that were completed, weight and height data
were recorded in 97 and 98% of patients respectively.
Compliance with completion of data were similar be-
tween sites with and without dedicated research coordi-
nators (6 of 12 sites) for the study (data not shown).
Discussion
The Canadian Childhood Nephrotic Syndrome Project
has been successful in recruiting patients from major
pediatric nephrology centres across Canada. We are
more than half-way to our recruitment goal of 400 pa-
tients. We have sufficient data to understand pattern of
glucocorticoid prescriptions, relapse rates, second line
agent use, and biopsy practices. Protocol adherence is
variable. Site and physician based variation was notable
in glucocorticoid exposure; however, full results regard-
ing how variation affects relapses will be available in the
year 2020.
We designed this study in the context of known wide-
spread practice variation within Canada and other
a b
c d
Fig. 5 Site specific differences of cumulative dose of glucocorticoid given (a) and the length of treatment (b) at first presentation. Further illustrated
are the site-specific differences of cumulative dose of glucocorticoid given (c) and length of treatment (d) at relapse. Data from 2 sites were not shown
due to low enrollment at the time of this report. Note: I Sites 1, 3,5,6,7,9,10 used protocol based treatments for nephrotic syndrome while Sites 2, 4, 8
did not. II Number of patients for sites 1–10 in first presentation graphs were 45, 3, 2, 37, 8, 29, 30, 22, 36 and 29 respectively. III Number of patients for
sites 1–10 in relapse graphs were 32, 2, 1, 22, 6, 20, 22, 17, 24 and 18 respectively
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jurisdictions among providers and centres in the man-
agement of nephrotic syndrome [8]. Such variability
should also be taken into consideration when designing
protocols to minimize glucocorticoid exposure, which is
an identified patient priority [11]. With the new data
from this study, we can determine the strength of associ-
ations between centre-, physician-, and patient-level
characteristics with glucocorticoid prescriptions, and
relapse rates. The final results, combined with recent
clinical trial data which shows that longer duration of
steroid treatment and/or higher dose (8 weeks of treat-
ment) does not reduce relapse rate [12–14], will help us
draft consensus protocols for the Canadian pediatric
nephrology community, which will aim to minimize
glucocorticoid toxicity and maximizing efficacy in avert-
ing relapses.
Despite an overall high consent rate (> 90%) from eli-
gible patients, the current recruitment rate would suggest
that we will not reach our target enrollment by end of the
study (December 2019). We have seen significant variabil-
ity in incidence of disease over time with spikes or lulls in
incidence of disease consistently across enrolling centers
(e.g. when incidence is low, it tends to be low at all cen-
tres). Therefore, challenges in attaining the target recruit-
ment may be due to the sporadic incidence of nephrotic
syndrome. Further, variability and turn over in research
staff at each site has been identified as a challenge for
recruitment throughout the time period of the study. For
sites with coordinators, we are confident that all poten-
tially eligible patients have been approached. There are
gaps in enrollment at sites where coordinators were ab-
sent for a period of time. To overcome these challenges,
we are planning to extend recruitment period as necessary
and apply for new funding to keep the study open.
Compliance with data entry is variable across centres.
Availability of research staff to enter data and follow pa-
tient’s clinical course in real time is important, but does
not lead to complete data entry at all sites with coordi-
nators. We also identified challenges in completing
records for semi-annual visits (only 66% with > 75% of
expected visits completed) and entering of full gluco-
corticoid taper data (only 90% complete) at the end of
treatment. We have not provided specific funding to
conduct ‘research visits’ and are relying on routine care
visits to occur in order for us to capture semi-annual
data – this poses a barrier to collection of complete data.
Measures to improve data collection completeness and
protocol adherence in the future includes creation of
quarterly data quality reports and real time data entry
monitoring by central study staff, and systematic
provision of feedback to sites to complete missing data.
One of the most important characteristics of this
study, and its strength, is its focus on patients with
glucocorticoid sensitive disease early in their disease
course. Most nephrotic syndrome registries focus on
glucocorticoid resistant patients and those who have had
a kidney biopsy [15, 16]. These are a minority among
the larger group of patients with nephrotic syndrome in
childhood, as most (80%) are typically not biopsied at
presentation [1]. Therefore, many registries contain a
biased sample of patients seen in pediatric nephrology
clinics. With successful recruitment, we have the oppor-
tunity to collect a heterogeneous sample of patients,
early in the course of disease. We acknowledge that
some patients may be seen by community-based pedia-
tricians (true estimate unknown, and difficult to ascer-
tain) in large urban centers (Vancouver, Toronto) as well
as in remote areas (particularly smaller provinces in At-
lantic Canada with no pediatric nephrologist). Despite
these exceptions, there is a well-established culture of
referral to pediatric nephrology of children with neph-
rotic syndrome in almost all major pediatric health
centres in Canada.
Our focus in this paper is to report on mid-study feasi-
bility and not to report on results. However, some re-
sults are notable even at this stage. We are observing a
consistent relapse rate of approximately 2 per patient
year of follow-up. There is wide variation in cumulative
dose of glucocorticoid prescribed between and within
sites for initial presentation. The variation is less marked
for relapses. This is an important observation that needs
to be considered in light of recent trial evidence which
shows that longer glucocorticoid duration or higher dose
does not reduce relapse rate [13, 14, 17]. We acknow-
ledge that practice is also changing based on emerging
evidence as we continue the study, and we will be cap-
turing this data. However, this observational data, taken
together with recent trial evidence, point to the need to
address the optimal dose and duration for initial presen-
tation and relapse using both evidence and consensus
based approaches.
Our study has a number of additional strengths.
Recruitment of physicians and linkage to patient data,
collection of detailed glucocorticoid prescriptions, and
enumeration of all relapses with the outcome of treat-
ments are a strength. In addition, the study infrastruc-
ture will allow us the opportunity to collect blood and
urine samples, in particular relapse remission paired
samples in order to conduct translational studies. The
combination of carefully collected clinical data, com-
bined with potential for biomarker data to be generated
from blood and urine samples will help us study patho-
genesis of disease and develop targeted treatments in
order to achieve transformational change in the manage-
ment of nephrotic syndrome.
The infrastructure built for this study was specifically
designed to conduct registry based clinical trials [18].
Once registered into this study, randomization of
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patients for future clinical trials, and refining protocols
for treatment of first presentation and relapses becomes
easily possible.
There are also several limitations to consider. We are
limited by the observational design of this study. There
may have been some referral bias, especially in larger
urban centres where community physicians are seeing
patients with nephrotic syndrome. These patients are
not included in the study due to feasibility of having
study coordinators on site at community practices, and
therefore some analysis such as seasonal variation in in-
cidence may have a degree of error due to under-report-
ing. We do not attempt to classify patients in terms of
relapse frequency as per convention for nephrotic syn-
drome (frequently relapsing, steroid dependent), as we
are describing the phenotype of the patients in an on-
going longitudinal study. The follow-up of patients in
the cohort has been sporadic in some centres due to lack
of access to research staff. We are not measuring patient
adherence to treatment. It is acknowledged that adher-
ence to treatment may be a major contributor to relapse
risk, and since our data do not contain this information
adherence will be an unmeasured confounder. We are
also not following patients after transfer to adult care,
due to funding limitations.
Conclusion
A longitudinal cohort study regarding idiopathic child-
hood nephrotic syndrome has been successfully launched
in Canada. Full results are expected in 2020. The infra-
structure of this study will be a key enabler for registry
based clinical trials and will spur innovative translational
studies regarding pathogenesis and treatment of nephrotic
syndrome.
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